Shopping Cart 0
Cart Subtotal
USD 0

Opiant Pharmaceuticals Inc (OPNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc (OPNT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13

Opiant Pharma and Titan Pharma Enter into Agreement 14

Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17

Lightlake Therapeutics To Enter Into Co-Development Agreement With King's College London 18

Licensing Agreements 19

Consort Medical Enter into Development Agreement with Opiant Pharma 19

Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23

Equity Offering 24

Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24

Opiant Pharma Raises USD12 Million in Public Offering of Shares 26

Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27

Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28

Asset Transactions 29

Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29

Opiant Pharmaceuticals Inc-Key Competitors 30

Opiant Pharmaceuticals Inc-Key Employees 31

Opiant Pharmaceuticals Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Nov 07, 2018: Opiant Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 33

Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 35

May 08, 2018: Opiant Pharmaceuticals Announces First Quarter 2018 Financial Results 37

Mar 07, 2018: Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update 38

Dec 04, 2017: Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results 39

Oct 13, 2017: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40

Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 42

Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 44

Corporate Communications 45

Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors 45

Jun 12, 2018: Opiant Pharmaceuticals Names Richard Daly As Board Director 46

Sep 05, 2017: Opiant Pharmaceuticals Announces Appointment of David O'Toole as Chief Financial Officer 47

Aug 28, 2017: Opiant Pharmaceuticals Announces Listing on the Nasdaq Capital Market 48

Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 49

Product News 50

02/28/2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder 50

Clinical Trials 51

Feb 12, 2018: Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose 51

Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine 52

Jul 19, 2017: Opiant Pharmaceuticals Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder 53

Mar 20, 2017: Opiant Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Opiant Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13

Opiant Pharma and Titan Pharma Enter into Agreement 14

Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15

Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16

Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17

Lightlake Therapeutics To Enter Into Co-Development Agreement With King's College London 18

Consort Medical Enter into Development Agreement with Opiant Pharma 19

Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20

Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23

Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24

Opiant Pharma Raises USD12 Million in Public Offering of Shares 26

Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27

Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28

Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29

Opiant Pharmaceuticals Inc, Key Competitors 30

Opiant Pharmaceuticals Inc, Key Employees 31

Opiant Pharmaceuticals Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Opiant Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.